ALDX Aldeyra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALDX

Price (delayed)

$3.91

Market cap

$230.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$103.12M

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's ...

Highlights
The company's EPS rose by 40% YoY and by 18% QoQ
The net income has grown by 39% YoY and by 18% from the previous quarter
The quick ratio is down by 43% year-on-year and by 3.2% since the previous quarter
ALDX's equity is down by 21% year-on-year and by 2.6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aldeyra.com
Peers: REGN

Key stats

What are the main financial stats of ALDX
Market
Shares outstanding
58.9M
Market cap
$230.28M
Enterprise value
$103.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$35.47M
EBITDA
-$35.21M
Free cash flow
-$30.33M
Per share
EPS
-$0.64
Free cash flow per share
-$0.51
Book value per share
$2.04
Revenue per share
$0
TBVPS
$2.52
Balance sheet
Total assets
$148.33M
Total liabilities
$28.53M
Debt
$15.66M
Equity
$119.8M
Working capital
$125.55M
Liquidity
Debt to equity
0.13
Current ratio
6.64
Quick ratio
6.42
Net debt/EBITDA
3.61
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-24.2%
Return on equity
-29.4%
Return on invested capital
-2,729.7%
Return on capital employed
-28.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALDX stock price

How has the Aldeyra Therapeutics stock price performed over time
Intraday
-0.51%
1 week
1.03%
1 month
34.83%
1 year
-60.98%
YTD
11.4%
QTD
19.57%

Financial performance

How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.79M
Net income
-$37.54M
Gross margin
N/A
Net margin
N/A
The net income has grown by 39% YoY and by 18% from the previous quarter
Aldeyra Therapeutics's operating income has increased by 32% YoY and by 15% QoQ

Growth

What is Aldeyra Therapeutics's growth rate over time

Valuation

What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 40% YoY and by 18% QoQ
ALDX's price to book (P/B) is 40% less than its last 4 quarters average of 3.2 and 31% less than its 5-year quarterly average of 2.8
ALDX's equity is down by 21% year-on-year and by 2.6% since the previous quarter

Efficiency

How efficient is Aldeyra Therapeutics business performance
The return on assets has increased by 22% year-on-year and by 14% since the previous quarter
The ROE has grown by 20% YoY and by 13% from the previous quarter

Dividends

What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALDX.

Financial health

How did Aldeyra Therapeutics financials performed over time
The current ratio has declined by 44% year-on-year and by 2.5% since the previous quarter
The quick ratio is down by 43% year-on-year and by 3.2% since the previous quarter
Aldeyra Therapeutics's debt is 87% lower than its equity
ALDX's equity is down by 21% year-on-year and by 2.6% since the previous quarter
The company's debt to equity rose by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.